Who is the manufacturer of infliximab?

Infliximab (Infliximab) was originally a chimeric anti-TNF-α monoclonal antibody jointly developed by Bristol-Myers Squibb and Janssen Biotech, a subsidiary of Johnson & Johnson. Its trade name is Remicade. This drug was approved by the US FDA in 1998. It was one of the first TNF-α inhibitors in the world approved for the treatment of Crohn's disease. It has since been widely used for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis and other chronic inflammatory diseases.

The original patent rights of infliximab belonged to Centocor (later acquired by Janssen). Currently, the original drug is still produced and sold by Janssen in many countries around the world, especially in North America and Europe. Remicade still has a wide market share. As patent protection gradually expires, some biosimilars have quickly entered the market. The most representative manufacturers include Celltrion of South Korea and Pfizer of the United States.

The infliximab biosimilar developed by Celltrion is called Remsima (sold as Inflectra in the United States). It is the first infliximab similar drug to be dual-approved by the EU and the United States. Pfizer has obtained sales rights through cooperation with Celltrion and widely promoted its version of infliximab in multiple countries. In addition, companies such as Biocon and Dr. Reddy’s in India have also launched biosimilar products targeting emerging markets.

In the Chinese market, Janssen is mainly responsible for the imported original drug of infliximab, while many domestic companies are actively developing and marketing infliximab biosimilars to meet the growing demand for treatment. Therefore, infliximab has gradually developed from an original biological drug monopolized by a few pharmaceutical companies to an important immunotherapy drug with the participation of many international pharmaceutical companies and an expanding global supply chain. The diversity of its manufacturers has also improved drug accessibility and patient treatment options.

Reference materials:https://www.drugs.com/infliximab.html